IP Library Granted Patent US 9,499,786
Granted Patent B2
US 9,499,786 · App. 13/766,100 · Granted Nov 22, 2016

Enriched population of human pluripotent cells with Oct-4 and Sox2 integrated into their genome

Inventors: James A. Thomson (Madison, WI); Junying Yu (Middleton, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N5/0607C12N5/0696C12N5/0606C12N2501/60C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2501/608C12N2502/99C12N2510/00C12N2799/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,786
App. No.
13/766,100
Granted
Nov 22, 2016
Kind
B2
Abstract

The present invention relates to methods for reprogramming a somatic cell to pluripotency by administering into the somatic cell at least one or a plurality of potency-determining factors. The invention also relates to pluripotent cell populations obtained using a reprogramming method.

Claims (11)

1. An enriched population of human pluripotent cells having a normal karyotype, wherein the human pluripotent cells comprise the genome of a single somatic cell of a postnatal individual human and further comprise an integrated non-native polynucleotide sequence encoding potency-determining factors comprising Oct-4 and Sox2.

2. The population of claim 1 , wherein the potency-determining factors additionally comprise at least one of Nanog and Lin28.

3. The population of claim 1 , wherein the population is obtained by exposing the somatic cell to a plurality of potency-determining factors under conditions sufficient to reprogram the somatic cell to a pluripotent cell.

4. The population of claim 3 , wherein the potency-determining factors additionally comprise at least one of Nanog and Lin28.

5. The population of claim 3 , wherein the exposing step comprises introducing a vector encoding one or more potency-determining factors into the somatic cell.

6. The population of claim 5 , wherein the vector is a viral-based vector.

7. The population of claim 2 , wherein the potency-determining factors are introduced to the somatic cell as a polynucleotide sequence comprising a nucleic acid sequence encoding a potency-determining factor operably linked to a heterologous promoter.

8. An enriched population of human pluripotent cells having a normal karyotype, comprising the genome of a somatic cell of a postnatal individual human, and further comprising integrated non-native polynucleotide sequences encoding potency-determining factors Oct-4, Sox2, and at least one of Nanog and Lin28.

9. A human pluripotent cell line derived from a somatic cell of a postnatal individual human, the somatic cell having a human somatic cell genome, by a process comprising

(a) contacting the human somatic cell to a plurality of potency-determining factors comprising Oct4 and Sox2 under conditions sufficient to reprogram the human somatic cell to a pluripotent cell comprising the human somatic cell genome and further comprising an integrated non-native polynucleotide sequence encoding the plurality of potency-determining factors; and

(b) culturing the pluripotent cell to obtain the human pluripotent cell line.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2013
From: YU, JUNYING; THOMSON, JAMES A.
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 029876/0345 →
CONFIRMATORY LICENSE Recorded Feb 25, 2013
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029865/0666 →
Continuity (5)
Division 12053440 · Mar 21, 2008
Provisional Application 60919687 · Mar 23, 2007
Provisional Application 60974980 · Sep 25, 2007
Provisional Application 60989058 · Nov 19, 2007
Related Publication 20130210138A1 · Aug 15, 2013